Walleye Capital’s BridgeBio Pharma BBIO Stock Holding History

Walleye Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$252K	Sell	3,400 -12,800	-79%	-$928K	﹤0.01%	3187
2025 Q4	$1.24M	Buy	16,200 +6,300	+64%	+$414K	﹤0.01%	2261
2025 Q3	$514K	Sell	9,900 -7,600	-43%	-$371K	﹤0.01%	2584
2025 Q2	$756K	Buy	17,500 +15,400	+733%	+$560K	﹤0.01%	2282
2025 Q1	$72.6K	Sell	2,100 -5,300	-72%	-$179K	﹤0.01%	3735
2024 Q4	$203K	Buy	+7,400	New	+$191K	﹤0.01%	3751
2024 Q3	–	Sell	-3,600	Closed	-$91.2K	–	5294
2024 Q2	$91.2K	Buy	3,600 +300	+9%	+$8.2K	﹤0.01%	4762
2024 Q1	$102K	Buy	+3,300	New	+$112K	﹤0.01%	4385
2023 Q4	–	Sell	-2,500	Closed	-$65.9K	–	4934
2023 Q3	$65.9K	Sell	2,500 -69,300	-97%	-$1.97M	﹤0.01%	4110
2023 Q2	$1.23M	Buy	71,800 +60,800	+553%	+$915K	﹤0.01%	1671
2023 Q1	$182K	Buy	+11,000	New	+$128K	﹤0.01%	2540

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's BBIO Position: Q1 2026 in Review

Walleye Capital increased its BridgeBio Pharma (BBIO) stake by 4,623% in Q1 2026, buying an estimated $16.2M and bringing the position to 228,593 shares worth $17M. The position accounts for 0.07% of the portfolio, ranked #236.

Walleye Capital first reported a position in BBIO in Q1 2021 and has held it in 12 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Walleye Capital held 228,593 shares of BridgeBio Pharma worth $17M as of Q1 2026.
Walleye Capital bought 223,753 BridgeBio Pharma shares in Q1 2026, an estimated $16.2M.
BridgeBio Pharma made up 0.07% of Walleye Capital's portfolio in Q1 2026, its #236 holding.
Walleye Capital first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 12 quarters since.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.